David Arterburn, MD, MPH, is a general internist and health services researcher who focuses on finding safe, effective, and non-stigmatizing ways to treat obesity. As an international leader in obesity research, his goal is to help individuals and families make treatment decisions that align with their values while sustaining their health over the long haul.
Dr. Arterburn's research portfolio includes studies of the impact of neighborhood environments on obesity, mindfulness-based interventions for weight loss, obesity pharmacotherapy, the long-term outcomes of bariatric surgery, and implementation of shared decision making tools and processes. He recently led the PCORnet Bariatric Study, a two-year, $4.5 million study comparing the health benefits and safety associated with the main types of bariatric surgery in 41 health systems in the United States. Funded by the Patient-Centered Outcomes Research Institute (PCORI), the study’s results give patients and their health care providers the information they need to decide which type of surgery is best for them. In July 2019, PCORI awarded Dr. Arterburn an additional $2.1 million to incorporate these new results into shared decision making at Kaiser Permanente Washington and the University of Pittsburgh Medical Center.
Over the past decade, Dr. Arterburn has collaborated with Kaiser Permanente Washington's specialty leadership to implement and evaluate shared decision making with patient decision aids to support elective surgical care. The approach has shown great promise for improving the quality of health care while simultaneously lowering the costs of care in some populations.
Dr. Arterburn collaborates extensively in his research and has federally-funded projects related to obesity and bariatric surgery with investigators at University of Washington (UW), Duke University, Harvard, University of Pittsburgh, University of Michigan, Wake Forest, and the Cleveland Clinic.
Dr. Arterburn joined Kaiser Permanente Washington Health Research Institute in 2006. In recognition of his contributions to science, he has been named an honorary Fellow of the American Society of Metabolic and Bariatric Surgery (FASMBS) and a Fellow of the American College of Physicians (FACP) and The Obesity Society (FTOS). Dr. Arterburn is past chair of the Adult Obesity Measurement Advisory Panel sponsored by the National Committee on Quality Assurance, founding chair of the Obesity Society's Health Services Research Section, and past chair of the Health Care Systems Research Network's Obesity Special Interest Group. In 2013 he co-chaired the National Institutes of Health Symposium on the Long-Term Outcomes of Bariatric Surgery. He is also an affiliate professor in the UW Department of Medicine.
Bariatric surgery; health services research; economics and risk adjustment; pharmaceutical outcomes research
Obesity prevention and control
Pharmaco-epidemiology, pharmacogenetics, pharmaceutical outcomes research
Shared decision making
Obesity prevention and control
Coleman KJ, Paz SR, Bhakta BB, Taylor B, Liu J, Yoon TK, Macias M, Arterburn DE, Crawford CL, Drewnowksi A, Figueroa Gray MS, Hansell LD, Ji M, Lewis KH, Moore DD, Murali SB, Young DR. Cohort profile: the Bariatric Experience Long Term (BELONG): a long-term prospective study to understand the psychosocial, environmental, health and behavioural predictors of weight loss and regain in patients who have bariatric surgery. BMJ Open. 2022 May 24;12(5):e059611. doi: 10.1136/bmjopen-2021-059611. PubMed
Lewis KH, Argetsinger S, Arterburn DE, Clemenzi J, Zhang F, Kamusiime R, Fernandez A, Ross-Degnan D, Wharam JF. Comparison of ambulatory health care costs and use associated with Roux-en-Y gastric bypass vs sleeve gastrectomy. JAMA Netw Open. 2022 May 2;5(5):e229661. doi: 10.1001/jamanetworkopen.2022.9661. PubMed
Howard R, Yang J, Thumma J, Arterburn DE, Ryan A, Chao G, Telem D, Dimick JB. Long-term comparative effectiveness of gastric bypass and sleeve gastrectomy on use of antireflux medication: a difference-in-differences analysis. Surg Obes Relat Dis. 2022 Apr 22:S1550-7289(22)00162-9. doi: 10.1016/j.soard.2022.04.016. PubMed
Kirwan JP, Courcoulas AP, Cummings DE, Goldfine AB, Kashyap SR, Simonson DC, Arterburn DE, Gourash WF, Vernon AH, Jakicic JM, Patti ME, Wolski K, Schauer PR. Diabetes remission in the Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Diabetes Care. 2022 Mar 23:dc212441. doi: 10.2337/dc21-2441. [Epub ahead of print]. PubMed
Basu A, Barton LJ, Fischer H, Reynolds K, Arterburn DE, Barthold D, Courcoulas A, Crawford CL, Fedorka PN, Kim BB, Mun EC, Murali SB, Zane RE, Coleman KJ. Comparative effectiveness of gastric bypass and sleeve gastrectomy on predicted 10-year risk of cardiovascular disease 5 years after surgery. Surg Obes Relat Dis. 2022 Mar 9:S1550-7289(22)00098-3. doi: 10.1016/j.soard.2022.02.021, [Epub ahead of print]. PubMed
Several new grants will fund research on effectiveness, safety, and equitable use of anti-obesity medications.
Study uses geographic data to track change over time.
Largest study to date helps patients weigh risks and benefits of surgery.
An evaluation with KPWHRI researchers looked at the impacts of the tax so far.